Globus Medical

GMED

Market cap $10.6B

Globus Medical is riding musculoskeletal market growth with spine, trauma and ortho gains, strong cash flow and a debt-free balance sheet.

NEW YORK, June 1, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Globus Medical, Inc. (NYSE: GMED) on behalf of the company's shareholders.  The investigation seeks to determine whether Globus Medical's directors breached their fiduciary duties in connection with recent corporate actions.

Globus Medical is shifting robotics deals to leases and rentals, aiming to expand its installed base and build recurring revenue streams.

Globus Medical's Q1 showed margin gains, strong spine and trauma growth, and rising robotics adoption as NuVasive synergies support 2026 targets.

Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.

Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.